Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

18 patients evaluable for efficacy achieved very good partial, partial or minor responses. Responses occurred in the first 28-day cycle of treatment at doses well below the maximum-tolerated dose for either lenalidomide or carfilzomib alone. Initial responses improved with continued therapy. Potent inhibition of the proteasome has been observed and the lenalidomide/dexamethasone combination does not appear to interfere with carfilzomib's activity.

"Results observed to date in our Phase 1b combination study of carfilzomib are very promising," said Michael Kauffman, M.D., Ph.D., Chief Medical Officer of Proteolix. "We believe that carfilzomib in combination with lenalidomide and dexamethasone should provide superior activity to lenalidomide and dexamethasone alone. In addition, the lack of overlapping toxicities and absence of peripheral neuropathy may allow for long-term dosing - and ultimately, sustained clinical benefit."

Dr. Wang presented interim data from the Phase 1b clinical trial during the Novel Therapeutics and Drug Resistance session in an oral talk, titled "#1070: PX-171-006: Phase IB Multicenter Dose Escalation Study of Carfilzomib (CFZ) plus Lenalidomide (LEN) and Low Dose Dexamethasone (LODEX) in Relapsed and Refractory Multiple Myeloma (MM) - Preliminary Results."

About Multiple Myeloma

According to the American Cancer Society, in 2009, approximately 20,500 new cases of multiple myeloma will be diagnosed in the United States. Newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment. Few patients are ultimately cured of their disease. In spite of advances in the treatment of multiple myeloma, this year alone, approximately 10,500 patients are expected to die of the disease.

About Carfilzomib<
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Synageva BioPharma Corp. ("Synageva") ... developing therapeutic products for rare disorders announced today ... Chief Operating Officer.  Reporting directly to Sanj ... Robert will oversee the planned global commercial launch ... LAL Deficiency, and will have responsibility for the ...
(Date:9/21/2014)... to produce ultra-thin "diamond nanothreads" that promise extraordinary properties, ... strongest nanotubes and polymers. A paper describing this discovery ... a professor of chemistry at Penn State University, will ... the journal Nature Materials . , "From a ... the threads we formed have a structure that has ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 ... urological and interventional radiology products and services, has ... subsidiary with Clinicon Corporation for its ... HealthTronics’ portfolio of minimally invasive, mobile, surgical technology—offering ... , Under the agreement, HealthTronics will make available ...
(Date:9/19/2014)... disease risks, the biological characteristics people care most about ... heightthe textbook example of a complex traitattributes like risk ... genetic and environmental influences, making it challenging to find ... typically mate two individuals that differ in key waysfor ... study their descendents, looking for genes that tend to ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2
... National Institutes of Health have turned simple baker,s yeast into ... for drugs to treat Parkinson,s disease. In a study ... researchers showed that they can rescue yeast cells from toxic ... the cells to make very small proteins called cyclic peptides. ...
... , WILMINGTON, Del., July 13 ParagonRx, a ... medications, has launched a new website - www.paragonrx.com ... companies needing information and assistance in complying with new FDA requirements ... and dangerous side effects. , , ...
... , , LEXINGTON, Mass. and HEIDELBERG, ... announced today the launch of the first human cancer biochip for ... Sequencing (NGS). The new catalog cancer biochip features 115 important genes ... by the Wellcome Trust Sanger Institute. , , ...
Cached Biology Technology:Novel drug discovery tool could identify promising new therapies for Parkinson's disease 2Novel drug discovery tool could identify promising new therapies for Parkinson's disease 3Novel drug discovery tool could identify promising new therapies for Parkinson's disease 4ParagonRx Creates New Website Featuring REMS Help Center for Pharma 2First Catalog Cancer Biochip for Sequence Capture Now Available from febit 2
(Date:9/21/2014)... of California, San Diego, have developed a program that ... activity of genes based on sequences of DNA. They ... to human embryonic cells in a paper published in ... of our cells have the same blueprint, the same ... lead author of the report. "Skin cells protect, nerve ...
(Date:9/19/2014)... the Jimmy Durante of dinosaurs a newly ... The new dinosaur, named Rhinorex condrupus ... Brigham Young University, lived in what is now ... Late Cretaceous period. , Rhinorex, which translates roughly ... close relative of other Cretaceous hadrosaurs like Parasaurolophus ...
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2New hadrosaur noses into spotlight 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... belonging to the genus Daphniola was found by a ... spring covered by snow on Mt. Parnassos, central Greece. This study ... . The new species, Daphniola eptalophos , ... a black penis with a small colorless outgrowth on the left ...
... Acinetobacter baumannii (MDR-AB) was found in the ... colonized or infected with the pathogen, according to a ... American Journal of Infection Control , the official ... Infection Control and Epidemiology. The study examined ...
... of Southern California (USC) professor Mary Ann Pentz, Ph.D., shows ... are more likely to drink alcohol in high school than ... September-October 2011 issue of the journal Alcohol and Alcoholism ... that may benefit from special prevention programs. "As you ...
Cached Biology News:Acinetobacter baumannii found growing in nearly half of infected patient rooms 2Underage drinking among close friends high indicator of future alcohol use by black teens 2
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
ANTI STENOTROPHOMONAS MALTOPHILIA...
... tube handling and reagent dispensing Holds: ... - 96 x 0.3ml U-bottom Omnistrips ... Non-Skirted Plate - Thermo-Fast® 96 Semi-Skirted Plate ... Multiple workstations can be securely stacked Can be stored ...
... well Magnetic-Ring Stand is designed for paramagnetic ... microplates. The stand has a plastic base ... plate footprint. The use of 96 extremely ... easy magnetic separation. With this magnetic stand, ...
Biology Products: